Results 141 to 150 of about 38,997 (290)

A Remote Chronic Disease Management Program to Improve Cardiovascular and Metabolic Outcomes in a Diverse Community‐Based Diabetic Population: Study Design of the TAMIS Trial

Journal of Evaluation in Clinical Practice, Volume 32, Issue 4, June 2026.
ABSTRACT Introduction Cardiovascular and cerebrovascular diseases are projected to expand in the coming decades as the main cause of death. This study outlines the escalating burden of cardiovascular diseases in low‐ and middle‐income countries (LMICs), particularly in Latin America (LA), which is expected to surpass that of other high‐population ...
Renato de Carvalho Barros, Andrea Stephanus, José Antonio Barbosa Filho, Evellyn Mariana, Yasmim Botelho, Thaiene M. M. Severino, Robson Conceição Silva, Lucila de Jesus Almeida, Cristiane Koeche, Bruno Gedeon, Mariana Guimarães Souza de Oliveira, Ana Carolina Augusto, Catarina Ferraz, F. Enzo, Gabriela de Lima, Julia Andrade Ibiapina, Giselle Pinto, Sérgio Henrique Rodolpho Ramalho, Ana Claudia C. Nogueira, Andrei C. Sposito, Alessandra M. Campos‐Staffico, Alexandre Anderson S. M. Soares, Luiz Sérgio F. de Carvalho   +22 more
wiley   +1 more source

Reduced risk of dementia with recombinant zoster vaccine in US adults age 65 or older

Alzheimer's &Dementia, Volume 22, Issue 5, May 2026.
Abstract INTRODUCTION Herpes zoster vaccines may lower the risk of dementia onset. We evaluated new‐onset dementia among US Medicare beneficiaries ≥65 years old following recombinant zoster vaccination (RZV). METHODS We matched one RZV‐exposed to two RZV‐unvaccinated on age, sex, and race/ethnicity. Individuals were ≥65 years old on the RZV dose 2 date
Susan dos Reis, Phuong Tran, Kareshma Mohanty, Alejandro Amill‐Rosario, Abree Johnson, Kathleen Ryan, Hannah Alsdurf, Driss Oraichi, Huifeng Yun   +8 more
wiley   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Resistance and differential susceptibility of Bidens pilosa and B. subalternans biotypes to ALS-inhibiting herbicides

Scientia Agricola, 2006
The frequent application of herbicides in agricultural areas may select resistant biotypes in weed populations, whose biological characteristics influence the speed and patterns of resistance.
Ramiro Fernando López-Ovejero, Saul Jorge Pinto de Carvalho, Marcelo Nicolai, Aluana Gonçalves Abreu, Maria Tereza Grombone-Guaratini, Roberto Estevão Bragion Toledo, Pedro Jacob Christoffoleti   +6 more
doaj  

Therapeutic Potential of Origanum majorana L. Essential Oil in Diabetes Mellitus: Insights From GC–MS Characterization, In Vivo Hypoglycaemic Studies, and In Silico Analyses

Chemistry &Biodiversity, Volume 23, Issue 5, May 2026.
Exploring the chemical profile and biological property of O. majorana EO. ABSTRACT Diabetes mellitus is a widespread metabolic disorder characterized by impaired glucose regulation. This study investigated the chemical composition and antidiabetic potential of Origanum majorana essential oil (EO) using integrated in vitro, in vivo, and computational ...
Mahmoud Houas, Mohammed Larbi Benamor, Elhafnaoui Lanez, Yahia Bekkar, Lotfi Bourougaa, Ouafa Boudebia, Rania Bouraoui, Aicha Adaika, Nafila Zouaghi, Salah Neghmouche Nacer, Lazhar Bechki, Touhami Lanez, Stefania Garzoli   +12 more
wiley   +1 more source

Resistence of Euphorbia Heterophylla L. to ALS-inhibiting herbicides in soybean

Scientia Agricola, 2005
Herbicides are widely used in soybean for weed control, and the selection pressure attributed to the repeated use of herbicides with similar modes of action on the same site has caused selection for resistant biotypes within and among previously ...
Gerson Augusto Gelmini, Ricardo Victória Filho, Maria do Carmo de Salvo Soares Novo, Márcio Luiz Adoryan   +3 more
doaj  

Emulating Six Cardiovascular Outcome Trials of Antidiabetic Drugs in Individuals with Type 2 Diabetes: Analyses Based on Real‐World Databases from Korea and Taiwan

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1265-1274, May 2026.
With the increasing volume of clinical evidence derived from large‐scale Asian real‐world data (RWD) and the growing interest in its use in regulatory decision‐making, it is important to conduct benchmarking exercises that evaluate whether studies using Asian RWD can generate similar conclusions as randomized controlled trials (RCTs).
Hwa Yeon Ko, Philip C. M. Au, Michael Chun‐Yuan Cheng, Ching‐Lung Cheung, Ahhyung Choi, Miyuki Hsing‐Chun Hsieh, Han Eol Jeong, Edward Chia‐Cheng Lai, Brian Meng‐Hsun Li, Kenneth K. C. Man, Jeremy A. Rassen, Daniel Hsiang‐Te Tsai, Shirley V. Wang, Ian C. K. Wong, Ju‐Young Shin, Sohee Park   +15 more
wiley   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1223-1234, May 2026.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

Two cases (a decade apart) of severe sulfonylurea-positive hypoglycemia associated with inhaled heroin use. [PDF]

JCEM Case Rep
Weisbrot B, Kim KY, Zacharia C, Hwang JL.   +3 more
europepmc   +1 more source

Not All GLP‐1 Receptor Agonists Are Alike: Real‐World Evidence of Differential Endocrine and Dermatologic Safety

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 4, May 2026.
ABSTRACT Aims Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are widely used for metabolic disorders, but emerging safety concerns include alopecia and reproductive or endocrine‐related adverse events (AEs). This study investigated the association between specific GLP‐1 RAs and these endocrine‐related AEs using a large‐scale pharmacovigilance ...
Nai Lee, Yun Kim
wiley   +1 more source